FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057796192> ?p ?o ?g. }

• W2057796192 endingPage "3412" @default.
• W2057796192 startingPage "3403" @default.
• W2057796192 abstract "Bosutinib, a dual Src/Abl tyrosine kinase inhibitor (TKI), has shown potent activity against chronic myeloid leukemia (CML). This phase 1/2 study evaluated the efficacy and safety of once-daily bosutinib 500 mg in leukemia patients after resistance/intolerance to imatinib. The current analysis included 118 patients with chronic-phase CML who had been pretreated with imatinib followed by dasatinib and/or nilotinib, with a median follow-up of 28.5 months. In this subpopulation, major cytogenetic response was attained by 32% of patients; complete cytogenetic response was attained by 24%, including in one of 3 patients treated with 3 prior TKIs. Complete hematologic response was achieved/maintained in 73% of patients. On-treatment transformation to accelerated/blast phase occurred in 5 patients. At 2 years, Kaplan-Meier-estimated progression-free survival was 73% and estimated overall survival was 83%. Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I. Bosutinib had an acceptable safety profile; treatment-emergent adverse events were primarily manageable grade 1/2 gastrointestinal events and rash. Grade 3/4 nonhematologic adverse events (> 2% of patients) included diarrhea (8%) and rash (4%). Bosutinib may offer a new treatment option for patients with chronic-phase CML after treatment with multiple TKIs. This trial was registered at www.clinicaltrials.gov as NCT00261846." @default.
• W2057796192 created "2016-06-24" @default.
• W2057796192 creator A5005182505 @default.
• W2057796192 creator A5005802663 @default.
• W2057796192 creator A5014558902 @default.
• W2057796192 creator A5015140142 @default.
• W2057796192 creator A5026190297 @default.
• W2057796192 creator A5044224344 @default.
• W2057796192 creator A5044355331 @default.
• W2057796192 creator A5052875031 @default.
• W2057796192 creator A5059723473 @default.
• W2057796192 creator A5083194684 @default.
• W2057796192 creator A5083442651 @default.
• W2057796192 creator A5090435894 @default.
• W2057796192 date "2012-04-12" @default.
• W2057796192 modified "2023-10-12" @default.
• W2057796192 title "Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure" @default.
• W2057796192 cites W1965429870 @default.
• W2057796192 cites W1979107490 @default.
• W2057796192 cites W1983700931 @default.
• W2057796192 cites W1983852790 @default.
• W2057796192 cites W1990020715 @default.
• W2057796192 cites W1992121712 @default.
• W2057796192 cites W1997026783 @default.
• W2057796192 cites W2028959752 @default.
• W2057796192 cites W2039531591 @default.
• W2057796192 cites W2039949576 @default.
• W2057796192 cites W2054251966 @default.
• W2057796192 cites W2060848548 @default.
• W2057796192 cites W2060882055 @default.
• W2057796192 cites W2101051382 @default.
• W2057796192 cites W2113344287 @default.
• W2057796192 cites W2115626434 @default.
• W2057796192 cites W2115628483 @default.
• W2057796192 cites W2116153687 @default.
• W2057796192 cites W2119238112 @default.
• W2057796192 cites W2125213800 @default.
• W2057796192 cites W2133697722 @default.
• W2057796192 cites W2151486690 @default.
• W2057796192 cites W2152713204 @default.
• W2057796192 cites W2158884958 @default.
• W2057796192 cites W2300848445 @default.
• W2057796192 cites W2314938037 @default.
• W2057796192 cites W2590231153 @default.
• W2057796192 doi "https://doi.org/10.1182/blood-2011-11-390120" @default.
• W2057796192 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4916559" @default.
• W2057796192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22371878" @default.
• W2057796192 hasPublicationYear "2012" @default.
• W2057796192 type Work @default.
• W2057796192 sameAs 2057796192 @default.
• W2057796192 citedByCount "275" @default.
• W2057796192 countsByYear W20577961922012 @default.
• W2057796192 countsByYear W20577961922013 @default.
• W2057796192 countsByYear W20577961922014 @default.
• W2057796192 countsByYear W20577961922015 @default.
• W2057796192 countsByYear W20577961922016 @default.
• W2057796192 countsByYear W20577961922017 @default.
• W2057796192 countsByYear W20577961922018 @default.
• W2057796192 countsByYear W20577961922019 @default.
• W2057796192 countsByYear W20577961922020 @default.
• W2057796192 countsByYear W20577961922021 @default.
• W2057796192 countsByYear W20577961922022 @default.
• W2057796192 countsByYear W20577961922023 @default.
• W2057796192 crossrefType "journal-article" @default.
• W2057796192 hasAuthorship W2057796192A5005182505 @default.
• W2057796192 hasAuthorship W2057796192A5005802663 @default.
• W2057796192 hasAuthorship W2057796192A5014558902 @default.
• W2057796192 hasAuthorship W2057796192A5015140142 @default.
• W2057796192 hasAuthorship W2057796192A5026190297 @default.
• W2057796192 hasAuthorship W2057796192A5044224344 @default.
• W2057796192 hasAuthorship W2057796192A5044355331 @default.
• W2057796192 hasAuthorship W2057796192A5052875031 @default.
• W2057796192 hasAuthorship W2057796192A5059723473 @default.
• W2057796192 hasAuthorship W2057796192A5083194684 @default.
• W2057796192 hasAuthorship W2057796192A5083442651 @default.
• W2057796192 hasAuthorship W2057796192A5090435894 @default.
• W2057796192 hasBestOaLocation W20577961921 @default.
• W2057796192 hasConcept C121608353 @default.
• W2057796192 hasConcept C126322002 @default.
• W2057796192 hasConcept C143998085 @default.
• W2057796192 hasConcept C197934379 @default.
• W2057796192 hasConcept C2777413986 @default.
• W2057796192 hasConcept C2777583451 @default.
• W2057796192 hasConcept C2778208673 @default.
• W2057796192 hasConcept C2778570526 @default.
• W2057796192 hasConcept C2778729363 @default.
• W2057796192 hasConcept C2778820342 @default.
• W2057796192 hasConcept C2779536868 @default.
• W2057796192 hasConcept C71924100 @default.
• W2057796192 hasConcept C90924648 @default.
• W2057796192 hasConceptScore W2057796192C121608353 @default.
• W2057796192 hasConceptScore W2057796192C126322002 @default.
• W2057796192 hasConceptScore W2057796192C143998085 @default.
• W2057796192 hasConceptScore W2057796192C197934379 @default.
• W2057796192 hasConceptScore W2057796192C2777413986 @default.
• W2057796192 hasConceptScore W2057796192C2777583451 @default.
• W2057796192 hasConceptScore W2057796192C2778208673 @default.
• W2057796192 hasConceptScore W2057796192C2778570526 @default.

• next